• Home
  • About Us
  • Products
  • Careers
  • Contact Us
  • Webmail
Picture
Anti-ulcerant

DPPI 
Description
Rabeprazole in DPPI is PPI (Proton Pump Inhibitor) shows faster onset of action and faster symptom control than other PPI. 
DPPI suppresses faster gastric acid secretion and is well tolerated with less potential drug interactions. 
Domperidone is pro-kinetic agent from the class of anti-dopaminergics. It selectively blocks dopamine receptors (D2) in Stomach & CTZ (Chemo receptor trigger zone) and stops reflux of acidic contents of stomach to esophagus. Moreover improves the peristalsis movement, pushing gastric content downward. 
DPPI  is developed in sustained release form for longer duration of action with convenience of once daily dose. 
Rabeprazole provides faster onset of action while domperidone ensures longer duration of action, thus combination of Rabeprazole & Domperidone is effective for treating symptoms of gastro-esophageal reflux disease. 

Indications:  
  • Dyspepsia
  • GERD
  • Gastritis
  • Drug induced Dyspepsia
  • Nausea & Vomiting associated with post operatives

Composition 

Each capsule contains:
Rabeprazole   20 mg
(Pellets in immediate release form)
Domperidone 30 mg 
(Pellets in sustained release form)

Dosage 
One capsule once a day.

Presentation
DPPI is available in a Alu-Alu perforated strip of 10 capsules.

Be the first of your friends to like this
Home   |   About Us   |   Products   |   Careers   |   Contact Us   |   Privacy Policy  

© 2012 - 2014 Therapeia Pharmaceuticals. All Rights Reserved.